{"id":"prednisone-or-equivalent","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Hyperglycemia"},{"rate":"5-20","effect":"Hypertension"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-15","effect":"Mood changes (anxiety, irritability)"},{"rate":"30-50","effect":"Osteoporosis (with chronic use)"},{"rate":"5-20","effect":"Infections (immunosuppression)"},{"rate":"5-10","effect":"Gastrointestinal upset"},{"rate":"variable","effect":"Cushingoid features (with chronic use)"}]},"_chembl":{"chemblId":"CHEMBL15720","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone acts as a glucocorticoid receptor agonist, entering cells and binding to cytoplasmic glucocorticoid receptors that translocate to the nucleus to modulate gene expression. This leads to decreased production of inflammatory mediators (IL-1, IL-6, TNF-α), reduced immune cell activation and proliferation, and suppression of both cellular and humoral immune responses. The drug is widely used for its potent anti-inflammatory and immunosuppressive effects across multiple therapeutic areas.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:56.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Lymphomas and leukemias (as part of combination chemotherapy)"},{"name":"Adrenal insufficiency"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT05789030","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07197749","phase":"EARLY_PHASE1","title":"Vitamin C With Steroids for Gastrointestinal GVHD","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"Graft-versus-host-disease (GVHD), Gastrointestinal","enrollment":35},{"nctId":"NCT06246513","phase":"PHASE3","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-15","conditions":"Limb-girdle Muscular Dystrophy","enrollment":17},{"nctId":"NCT03153527","phase":"PHASE4","title":"Taper Or Abrupt Steroid Stop: TOASSTtrial","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-05-31","conditions":"Inflammatory Disorder, Autoimmune","enrollment":530},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT06126380","phase":"PHASE2","title":"Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Eledon Pharmaceuticals","startDate":"2023-10-25","conditions":"Kidney Transplant Rejection","enrollment":132},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Wegener Granulomatosis, Microscopic Polyangiitis","enrollment":117},{"nctId":"NCT03721965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-12-31","conditions":"Acute Graft-versus-host Disease","enrollment":2},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT06598332","phase":"EARLY_PHASE1","title":"5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2025-08","conditions":"Graft-Versus-Host Disease(GVHD)","enrollment":""},{"nctId":"NCT01731561","phase":"PHASE3","title":"Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11-16","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Renal Limited Forms","enrollment":166},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT06172361","phase":"PHASE3","title":"Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Polymyalgia Rheumatica","enrollment":98},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT06952686","phase":"PHASE3","title":"A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants","status":"WITHDRAWN","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2025-06-30","conditions":"Muscular Dystrophies, Limb-Girdle","enrollment":""},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT03384654","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-14","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":47},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT03811366","phase":"NA","title":"Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06-01","conditions":"Uveomeningoencephalitic Syndrome, Inflammation, Choroid Disease","enrollment":12},{"nctId":"NCT06887517","phase":"","title":"Chinese Rheumatism Biobank(CRB)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-02-10","conditions":"Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT04556617","phase":"PHASE1, PHASE2","title":"PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Opna Bio LLC","startDate":"2020-09-21","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":19},{"nctId":"NCT05707156","phase":"","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-07-05","conditions":"Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis","enrollment":12032},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT06756061","phase":"PHASE2","title":"Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity","status":"RECRUITING","sponsor":"Byung-Sik Cho","startDate":"2025-01-15","conditions":"GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation","enrollment":88},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT06780462","phase":"PHASE3","title":"Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-15","conditions":"Behcet Syndrome","enrollment":134},{"nctId":"NCT00686335","phase":"PHASE2","title":"A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Asthma","enrollment":12},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT06652126","phase":"","title":"Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2024-11-01","conditions":"Critically-ill Patients","enrollment":1000},{"nctId":"NCT05102448","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-01","conditions":"Takayasu Arteritis","enrollment":76},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT06486337","phase":"PHASE2","title":"CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"NHL","enrollment":197},{"nctId":"NCT05740449","phase":"PHASE1, PHASE2","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"WITHDRAWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":""},{"nctId":"NCT02426502","phase":"NA","title":"Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2016-04","conditions":"End-Stage Renal Disease","enrollment":76},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT05700565","phase":"","title":"Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype","status":"RECRUITING","sponsor":"Lucie Heinzerling","startDate":"2022-01-01","conditions":"Immune-related Adverse Event","enrollment":50},{"nctId":"NCT06266221","phase":"PHASE3","title":"Severe Erythema Multiforme - CORTICO","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-05-01","conditions":"Erythema Multiforme","enrollment":96},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT04054375","phase":"PHASE2","title":"Weekly Steroids in Muscular Dystrophy","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-07-01","conditions":"Limb-girdle Muscular Dystrophy, Becker Muscular Dystrophy","enrollment":20},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT05179733","phase":"PHASE3","title":"The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-03-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":280},{"nctId":"NCT00323960","phase":"PHASE3","title":"Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2006-05-31","conditions":"Juvenile Dermatomyositis","enrollment":139},{"nctId":"NCT02490878","phase":"PHASE2","title":"Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2016-04","conditions":"Radionecrosis, Brain Metastases","enrollment":19},{"nctId":"NCT01086540","phase":"PHASE2","title":"Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-24","conditions":"Systemic Sclerosis-Associated PAH","enrollment":57},{"nctId":"NCT05625581","phase":"","title":"Tofatib Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-11-10","conditions":"IgG4-related Disease","enrollment":40},{"nctId":"NCT02133924","phase":"PHASE2","title":"Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"John Levine","startDate":"2016-08","conditions":"Acute Graft Versus Host Disease","enrollment":76},{"nctId":"NCT04799262","phase":"PHASE2","title":"Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2021-01-01","conditions":"Polymyalgia Rheumatica, Effect of Drug, Safety Issues","enrollment":14},{"nctId":"NCT05506033","phase":"NA","title":"Optimization of Glucocorticoid Taper Strategies for SLE-ITP","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-08-15","conditions":"Lupus Erythematosus, Systemic, Purpura, Thrombocytopenic, Idiopathic, Glucocorticoids","enrollment":120},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT03632187","phase":"PHASE3","title":"Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2018-12-13","conditions":"Polymyalgia Rheumatica","enrollment":34},{"nctId":"NCT03853044","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-12-29","conditions":"Angioimmunoblastic T-cell Lymphoma","enrollment":23},{"nctId":"NCT05200312","phase":"PHASE2","title":"A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT04782700","phase":"NA","title":"P-Co-Li (Pulmonary Covid-19 Study)","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2021-04-01","conditions":"Covid19, Lung Inflammation, Hypoxemic Respiratory Failure","enrollment":""},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT05135442","phase":"PHASE4","title":"Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-12-01","conditions":"Thrombotic Thrombocytopenic Purpura, Acquired","enrollment":30},{"nctId":"NCT05105347","phase":"PHASE4","title":"Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-11-10","conditions":"Uveitis","enrollment":130},{"nctId":"NCT03852537","phase":"PHASE2","title":"Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-12-02","conditions":"Pneumonia","enrollment":44},{"nctId":"NCT02406651","phase":"PHASE1, PHASE2","title":"Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2016-05-12","conditions":"Acute Graft vs Host Disease","enrollment":30},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT04944524","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-07-01","conditions":"Granulomatosis With Polyangiitis","enrollment":66},{"nctId":"NCT04942314","phase":"","title":"Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study","status":"UNKNOWN","sponsor":"Jia Deng","startDate":"2021-07-01","conditions":"Systemic Lupus Erythematosus","enrollment":600},{"nctId":"NCT04762784","phase":"PHASE4","title":"A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-01","conditions":"Idiopathic Retroperitoneal Fibrosis","enrollment":40},{"nctId":"NCT04762810","phase":"PHASE4","title":"A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-03","conditions":"Idiopathic Retroperitoneal Fibrosis","enrollment":40},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT04660565","phase":"PHASE4","title":"Belimumab Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01","conditions":"IgG4-related Disease","enrollment":60},{"nctId":"NCT01994850","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-11","conditions":"CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma","enrollment":32},{"nctId":"NCT02462252","phase":"PHASE2","title":"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2015-10","conditions":"Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT02260934","phase":"PHASE2","title":"Rituximab and Belimumab for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-09","conditions":"Lupus Nephritis","enrollment":43},{"nctId":"NCT03133897","phase":"PHASE3","title":"Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study","status":"TERMINATED","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2018-03-05","conditions":"Asthma","enrollment":20},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00263562","phase":"PHASE3","title":"Steroid Treatment for Sickle Cell Pain Crisis","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2005-12-01","conditions":"Sickle Cell Disease, Vaso-occlusive Crisis","enrollment":18},{"nctId":"NCT03584802","phase":"NA","title":"Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-05-16","conditions":"Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":40},{"nctId":"NCT02176031","phase":"PHASE2","title":"Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"Graft Versus Host Disease","enrollment":21},{"nctId":"NCT04295655","phase":"NA","title":"Physiotherapy in Hypoxic AECOPD Patients","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2019-12-01","conditions":"COPD Exacerbation","enrollment":36},{"nctId":"NCT01753401","phase":"PHASE4","title":"Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-01","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":38},{"nctId":"NCT01327573","phase":"PHASE1","title":"Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation","status":"COMPLETED","sponsor":"Sanjay Kulkarni","startDate":"2011-03","conditions":"Kidney; Complications, Allograft","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":343,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prednisone (or equivalent)","genericName":"Prednisone (or equivalent)","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune conditions (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Lymphomas and leukemias (as part of combination chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}